Latest News

Ceapro Awarded Research Contribution from National Research Council of Canada for the Development, Demonstration and Testing of its Proprietary Pressurized Gas Expanded Technology (PGX) – Unique PGX enabling technology expected to generate novel bio-based products with improved purity and functionality in several industrial applications

EDMONTON, ALBERTA – November 12, 2015 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the National Research Council of Canada (NRC) through its Industrial Research

Read more

Ceapro Presents Unique Advantages of its Disruptive Pressurized Gas Expanded Technology (PGX) at 2015 Composites at Lake Louise

EDMONTON, ALBERTA – November 10, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that Bernhard Seifried, Ph.D., Ceapro’s Senior Research Scientist and a co-inventor of its

Read more

Ceapro Inc. Reports Second Quarter 2015 Financial and Operations Results

EDMONTON, ALBERTA – August 26, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Presents Unique Advantages of Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology

EDMONTON, ALBERTA – July 21, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, presented the unique advantages of its proprietary and novel Pressurized Gas eXpanded (PGX) platform

Read more

Ceapro to Present on Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology – Co-inventor of PGX, Bernhard Seifried, Ph.D., to present on Ceapro’s platform technology for novel biopolymer applications

EDMONTON, ALBERTA – July 9, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that an abstract on its novel Pressurized Gas eXpanded (PGX) platform processing

Read more

Ceapro Featured at the 12th International Congress on Engineering and Food (ICEF12) – Gilles Gagnon, M.Sc., MBA, Ceapro’s President and CEO, Honorary Guest VIP Speaker at the ICEF opening ceremony – Bernhard Seifried, Ph.D., Senior Research Scientist and co-inventor of Ceapro’s PGX Technology to present on June 17, 2015

EDMONTON, ALBERTA – June 15, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced its featured participation in the 12th International Congress on Engineering and Food (ICEF12)

Read more

Ceapro Announces Election of Directors at 2015 Shareholders’ Meeting

EDMONTON, ALBERTA – June 9, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William

Read more

Ceapro Inc. Reports First Quarter 2015 Financial and Operations Results

EDMONTON, ALBERTA – June 1, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-months ended March 31, 2015 and provided

Read more

Ceapro to Develop Enabling Pressurized Gas Expanded Technology (PGX) at Commercial and Demonstration Scale – Scale-up of unique, patented PGX enabling technology expected to generate numerous novel bio-based products with improved purity and functionality in several industrial applications

EDMONTON, ALBERTA – May 28, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, announced today it will embark on a scale-up of its proprietary PGX technology

Read more

Ceapro Announces Appointment of New Chief Financial Officer

EDMONTON, ALBERTA – May 5, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine

Read more
Page 4 of 10« First...23456...10...Last »